Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

33 y/o male used topical fin/min and dermaroll biweekly, resulting in increased hair density and significant regrowth. He got the solution from Hims and also used a DermaPen for microneedling.

Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The user shared progress pictures after 3 months of using topical finasteride, minoxidil, and microneedling for hair loss. They plan a hair transplant at 6 months, and others inquired about microneedling frequency and depth.

Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.

A 26-year-old male shared his 3-month progress using Minoxidil and finasteride daily, microneedling weekly, and occasional vitamin D3. A commenter praised his impressive results.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The user is updating on their 3-month progress using minoxidil (0.5mg twice daily) and microneedling once a week. They plan to consult a doctor about adding finasteride to their regimen.

The conversation is about someone using finasteride and minoxidil along with microneedling as a treatment for hair loss, and there's a mention of scalp tattooing as an alternative or additional approach. Some responses mock the approach, while others inquire about the specifics of the treatment and its effectiveness.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The user is happy with hair regrowth after using finasteride, minoxidil, and microneedling for three months. Others comment on the progress and ask about the routine, lighting, and potential side effects.

9 Month Update: Topical Fin/Min (0.3%, 6%), Weekly Microneedle 1.5mm, 40 Years Old. User shares progress pictures and discusses hair loss treatments used.

A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.

Dermmatch is wind and water proof, but requires more hair to look good. Using both Dermmatch and hair fibers together can provide better coverage and a more natural look.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Microneedling, comparing dermarollers and dermastamps as treatments for hair loss, and the effectiveness of each. Dermastamps are considered cheaper than dermapens, but users have varying opinions on which method is more effective with less pain.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

A user shared progress pictures after 6 months of using a topical treatment with 6% Minoxidil and 0.3% Finasteride, showing improved hair density. Other users encouraged the progress and suggested adding a derma stamp for better results.

User shared 8-month progress using daily topical Fin/Min, weekly microneedling, and supplements (biotin, zinc, saw palmetto, collagen). Others praised hairline regrowth and requested temple photos.

The user is experiencing hair loss and has been using treatments like minoxidil, finasteride, and ciclopirox olamine. Despite these treatments, they are concerned about increased shedding, dandruff, and possible additional hair loss conditions.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.